Stanford University
Showing 971-980 of 7,747 Results
-
Arianne Caudal
Instructor, Cardiovascular Institute
BioDr. Arianne Caudal is a postdoctoral fellow at the Stanford Cardiovascular Institute with research interests in cardiac metabolism, disease modeling, and drug discovery. Dr. Caudal received her PhD in Biochemistry from the University of Washington, after conducting thesis work on mitochondrial metabolism and protein-protein interactions in the heart.
-
Alejandro Sebastian Cazzulino
Clinical Instructor, Orthopaedic Surgery
BioI am originally from New York City. I went to Columbia University, where I earned my BA in Neuroscience and Behavior. I then went to the Perelman School of Medicine at the University of Pennsylvania, where I earned my MD. I then moved to the West Coast and completed my orthopedic surgery residency training at the University of California, San Francisco (UCSF). I am now an Adult Reconstruction Fellow in the Department of Orthopedic Surgery at Stanford University.
-
Lynette Cegelski
Monroe E. Spaght Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsResearch in the Cegelski laboratory is driven by the need to uncover and define the chemistry that underlies outstanding challenges in human health, the environment, and sustainability. Beyond discovery, we use chemistry as a tool to innovate and create solutions to these pressing problems. The laboratory is highly interdisciplinary, designing experimental approaches to understand how complex biological systems are built, organized, and controlled, and then perturb and influence assembly processes. The lab develops new methods and uniquely leverages: (1) small molecules in new biochemical assay development, chemical genetics approaches, and therapeutic discovery in infectious diseases, (2) fluorescence and electron microscopy coupled to analytical HPLC, mass spectrometry, and complementary biochemical techniques, and (3) spectroscopy, particularly solid-state NMR, to uncover new “dark matter” and define chemistry in insoluble, heterogeneous and complex assemblies relevant to human health, plants, and the ocean.
Long-standing efforts in the laboratory focus on defining mechanisms underlying bacterial biofilm formation and identifying new antibiotic and anti-virulence strategies, including advancing therapeutic candidates for the most difficult-to-treat infections. Through these efforts, we uncovered a new chemical structure in nature: phosphoethanolamine (pEtN) cellulose. Cellulose is the most abundant biopolymer on earth and this discovery provided the first experimental validation of a naturally produced chemically modified cellulose. We are developing alternatively modified celluloses and polysaccharides and advancing new solutions for ecofriendly, sustainably sourced, and recyclable materials. Collectively, our projects span disciplines from molecular structure and assembly chemistry to living microbial communities and natural marine systems, while aiming to translate fundamental discoveries into therapeutic and materials solutions. -
Sierra Mei Lin Centkowski, MD
Clinical Assistant Professor, Dermatology
Clinical Assistant Professor, DermatologyBioDr. Sierra Mei Lin Centkowski is a board-certified Clinical Assistant Professor of Dermatology at Stanford University. She received both her medical degree and Master’s in Bioethics from the Perelman School of Medicine at the University of Pennsylvania and completed her dermatology residency at Stanford. Her clinical interests include general dermatology, including skin cancer, acne, psoriasis, atopic dermatitis and dermatologic surgery. She believes that patient empowerment and partnership provide the foundation for effective, compassionate and holistic care.
-
Alma-Martina Cepika
Assistant Professor of Surgery (General Surgery)
Current Research and Scholarly InterestsCepika Lab studies human immune tolerance. Using cellular immunology, genomics, and gene engineering, we aim to understand: 1) the role of human thymic regulatory T cells (Tregs) and inducible type 1 regulatory T (Tr1) cells in resistance to anti-tumor immunity and cancer immunotherapy, and 2) the interplay between innate and adaptive immunity in the pathogenesis of human inflammatory bowel disease (IBD). Our overarching goal is to leverage our discoveries for improving patient outcomes.
